- Home
- SRBK vs BOLD Comparison
SRBK vs BOLD Comparison
Compare SRBK & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | SRBK | BOLD |
|---|---|---|
| Founded | 1887 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 149.8M | 57.5M |
| IPO Year | 2023 | 2024 |
Fundamental Metrics
Financial Performance| Metric | SRBK | BOLD |
|---|---|---|
| Price | $19.64 | $2.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 23.6K | ★ 187.4K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.04% | N/A |
| EPS Growth | ★ 138.36 | 32.47 |
| EPS | ★ 0.31 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $63.23 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.90 | $0.96 |
| 52 Week High | $20.20 | $2.79 |
Technical Indicators
Market Signals| Indicator | SRBK | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 53.23 | 67.87 |
| Support Level | $18.48 | $2.35 |
| Resistance Level | $19.61 | $2.64 |
| Average True Range (ATR) | 0.53 | 0.09 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 51.70 | 69.77 |
Price Performance
Historical ComparisonAbout SRBK SR Bancorp Inc.
SR Bancorp Inc principal business is to acquire deposits from individuals and businesses in the communities surrounding offices and to use these deposits to fund loans.
About BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.